|
|
|
||
|
|
|
|
人生一定要有的八個朋友: 推手(Builder)、 支柱(Champion)、 同好(Collaborator)、 夥伴(Companion)、 中介(Connector)、 開心果(Energizer)、 開路者(Mind Opener)、 導師(Navigator)。 chutze@bostonorange.com ******************* All rights of articles and photos on this website are reserved.
|
|
|
||
|
|
|
|
波士頓市長吳弭 (Michelle Wu)和麻州眾議會財政委員會主席麥家威 (Aaron Michlewitz) 對麻州地鐵都有看法。 (檔案照片,周菊子攝) |
6月底,波士頓市長吳弭在紐英崙至孝篤親公所慶祝陳孔恩榮升波士頓市警察局社區參與總監的宴會中被問及MBTA一事時,笑說索性把MBTA交給波士頓市來營運。
MBTA在過去這一年中發生的大事故,包括2021年的7月30日綠線地鐵在Pleasant街車站撞上前一輛列車,導致27人送醫治療;9月11日,波士頓大學教授
David Jones在多徹斯特 (Dorchester)
靠近JFK/麻州大學車站,一個已關閉,生鏽了樓梯上跌落,摔死了;9月26日,後灣車站的上升電梯突然倒轉向下,使得電梯上站在前面的人相繼疊壓在後面的人身上,有人流血受傷,9人送醫;2022年的1月21日,由於Wilmington那兒提醒車輛離開軌道的欄杆和閃爍燈號沒及時啟動,一輛通勤火車撞了一名婦女的車,把該名婦女撞死了;4月10日,在紅線地鐵百老匯
(Broadway)車站,39歲的乘客 Robinson Lalin在車門關上時,手臂卡住,被地鐵拖行而死;6月1日,兩列綠線地鐵在政府中心車站互撞脫軌,導致4名駕駛送醫。
最新這宗是7月21日一大早7點以前,橘線地鐵從麥德福市
(Medford) 開進尚莫維爾市
(Somerville)市的”集合 (Assembly)車站”時,第一節車廂竟起火了,把車上200多名乘客嚇得紛紛敲破窗戶,奪路而逃,還有一名女子索性縱身跳進橋下的神秘
(Mystic)河,再游上岸。
聯邦政府交通行政局
(The Federal Transit Administration) 因為這一連串事故,五月中時派員到麻州調查,揚言為了公眾安全,考慮接管麻州地鐵。
7月21日的事故發生後,麻州州長查理貝克在GBH電台的「問州長
(Ask the Governor)」節目中,就麻州眾議員William
Straus稱麻州地鐵已經不再能洽當的服務大眾,應該由麻州交通廳
(MassDOT) 接收這意見表達看法時,表示他不反對探討解散麻州地鐵這機構的可行性。查理貝克州長
6月底回應本刊提問時,先指出麻州地鐵之所以是半官方機構,並不由麻州政府管轄,源於其營運經費來自許多不同管道,接著也認為把MBTA納為州政府機構的做法值得探討。
波士頓市長吳弭今日在WBUR電台的訪談節目中直言,MBTA是個十分老舊的系統,許多車廂已超過使用年限,軌道需要更換,運作科技也很過時。現在人們看到政府有經費,卻沒有放進麻州地鐵的更新,改善及維修,才會出現一連串的問題。
受新冠病毒疫情影響,中華表演藝術基金會主辦的這夏日系列音樂會(Summer FREE Concerts @ NEC),已中斷兩年,今年終於恢復,已排定15場免費音樂會,將於8
8月2
這15場夏日系列音樂會的演出者介紹和曲目詳請,已在中華表演藝術基金會的官網上公佈,ht
23位大、中、小提琴、鋼琴、及聲樂音樂家中,有享譽全
今年的傅聰國際協奏曲比賽,指定曲目是貝多芬第五號降E
這10名複賽入圍者,有1 人因簽證問題退出,其他9人將來到紐英崙音樂學院,參加現場複賽,爭取成為5名決賽入圍者之一。
中華表演藝術基金會官網上,已公佈10名晉級複賽者的簡介及20分鐘獨奏曲,以及負責複賽及決賽的5名評委簡介,包括三名紐英崙音樂學院的鋼琴教授
協奏曲比賽第一名獎金5000美元,第二名1500美元。
ISCT publishes conclusions and consensus from its 2022 Annual Meeting
ISCT provided post-pandemic venue for the entire cell and gene therapy sector to generate solutions to the major barriers to providing therapies to patients
Vancouver, Canada, July 25, 2022 - The International Society for Cell & Gene Therapy (ISCT), the global society of clinicians, researchers, regulators, technologists, and industry partners dedicated to the translation of cell and gene therapy (CGT) into safe and effective therapies to improve patients’ lives, today announces the conclusions and consensus from its international ISCT 2022 Annual Meeting.
The ISCT Annual Meeting, held this year in San Francisco, US, between May 4-7, 2022, is the largest global yearly summit event for all those involved in the cell and gene therapy translation sector. It has set the aims, policies, solutions, and consensus path forward for the sector over each successive 12 months, addressing the biggest bottlenecks in cell and gene therapy development. The ISCT Annual Meeting is designed to connect cell and gene therapy translation professionals to educate, inspire, network and collaborate.
In total, 1,646 cell and gene therapy experts from 38 countries attended in person the 2022 meeting, representing all stakeholders in the cell and gene therapy field across industry, academic and regulatory spheres. Of these attendees, 59 percent were from industry, including therapy developers, manufacturers, other supply chain providers and investors. 41 percent were from academia, government and non-profit organizations. The largest sector increase in attendance was from manufacturing, with 23 percent of in-person attendees at ISCT 2022, raised from 11 percent in the virtual ISCT 2021 meeting. In addition, there were over 2,000 in-person B2B partnering meetings, a 400 percent increase on previous years.
ISCT 2022 featured a revamped program addressing new translational challenges arising through the rapid and sustained growth of the field. “The exponential growth phase in the field of cell and gene therapy continues as a growing number of therapies are being approved and new innovations are created,” said Anthony Ting, Chief Commercialization Officer, ISCT. “The development of a novel cell or gene therapy for the treatment of patients with high unmet medical needs is a process that requires communication and collaboration across multiple disciplines including scientists, industries including both therapeutic developers and technology enablers, as well as clinicians, regulators, and the patients themselves. The continuation of this cross-sector collaboration is vital.”
The ISCT 2022 scientific program, renamed the Translational Pathway Program, integrated perspectives across the CGT sector to address key topics at the various stages of translation. The program was structured to mirror therapeutic development, launching with addressing barriers to early translational research, proceeding through the various phases of clinical trials, and concluding with patient access and commercialization considerations.
“The new meeting format allowed delegates to attend sessions based not only on cell types but also product development pathways,” said Bambi Grilley, Co-Chair, ISCT 2022. “The success of this new format is largely reflective of the fact that cell and gene therapies now run the gamut of pre-clinical to post-marketing.”
Launching the Translational Pathway Program, the Presidential Plenary provided clarification as to the scale of increases of gene editing and gene modified therapies, including those now commercially available in many countries. In addition, there were extensive discussions on equality of access issues, specifically how to widen patient access within and across countries, and the commercial and regulatory challenges in developing advanced cell and gene therapies for rare diseases.
ISCT hosting the 33 roundtables at the Annual Meeting provided key stakeholders a platform, unique in the cell and gene therapy sector, to debate and provide consensus to guide ISCT and the wider sector on a full range of topics, barriers and milestones currently affecting cell and gene therapy. The roundtables enabled delegates to ask questions, join in debates, and participate in problem-solving to develop impactful solutions that shape their field.
The roundtables covered the full range of therapies, including innovation, clinical translation, product launch and patient access for CAR-Ts, MSCs, iPSCs, and a variety of gene therapies. The topics included the relationship between investors and the CGT sector, expanded access and hospital exemption, managing the CGT workforce and skills crisis, product development, managing risks, potency assays, toxicity, sterility, starting materials and donors, supply chains and chain of custody and identity.
Headline conclusions from debates in the roundtables included the requirement for region, and even country-specific solutions, whilst historically organizations in the cell and gene therapy industry had tried to present single international solutions, with limited efficacy. Similarly, solutions need to be different within different technologies and fields within the CGT sector. It was also agreed that the sector still needs to form more collaborations to serve patient requirements in the future. Finally, standardization across the reporting and qualification of facilities collecting and administering commercially sponsored products is vital.
Workforce development was a central focus of the Roundtable Program, aiming to provide solutions to the dearth of qualified personnel to manufacture cell and gene therapy products. Training programs are limited and most personnel are trained on-the-job. Middle management roles are also particularly challenging to fill because personnel with experience are in high demand and can be lured away to the highest paying opportunity. Delegates shared experiences from their laboratories and participated in outlining solutions to the workforce shortage. The consensus was that the field needs to think ‘outside the box’ to develop hands-on training programs, not only for graduates, but also for experienced individuals looking to change careers. One opportunity to consider is academic collaborations with industry to train personnel. ISCT will look to facilitate these partnerships, utilizing the strong ties that are present with the ISCT Industry Committee.
“The COVID pandemic has provided an ultimate clarification
of the urgent need for therapeutic development for a range of therapies at the
same time as preventing in-person meetings for these therapies to be discussed.
The onus was therefore on ISCT, at its thirtieth anniversary, to provide the
platform for the sector to meet again for the first time in three years. This
platform enabled all stakeholders in the sector to reach fresh consensus and
conclusions about the new priorities for the cell and gene therapy space,” said
Bruce Levine, outgoing President, ISCT. “ISCT broadened its focus, through a
whole series of roundtables, to cover wider challenges experienced across the
industry, from generating return on investment to managing the supply chain.
ISCT will continue to monitor the efficacy of solutions generated at the
meeting and continue to work with all stakeholders to ensure an increasing
number of patients are able to benefit from cell and gene therapies.”